摘要
测定咽立爽口含滴丸在大鼠各组织中龙脑、龙脑-2-O-葡萄糖醛酸苷(B2G)、薄荷脑、薄荷脑-1-O-葡萄糖醛酸苷(M1G)、樟脑和甘草酸的含量,探讨其在各组织的分布特征。灌胃给予正常SD大鼠咽立爽口含滴丸,于给药后不同时间点采集血浆和9种组织(心、肝、脾、肺、肾、肠、脑、胃、咽),建立气相色谱-质谱(GC-MS)和超高液相色谱-串联质谱(UPLC-MS/MS)定量分析方法,测定血浆和组织样本中6种成分的含量,并比较各组织之间的分布差异。结果显示,6种原型成分及代谢产物均被吸收入血且在体内广泛分布,在血浆和各组织中均于30 min内达峰值,90 min时被逐渐消除。原型成分龙脑、薄荷脑和樟脑主要分布于胃、肠;甘草酸主要分布于胃、肠和咽,在其他组织中仅有少量分布。代谢产物B2G和M1G在肠、肝、肾中分布较多。其中B2G和甘草酸在咽中分布较多。该研究揭示了咽立爽口含滴丸原型成分及代谢产物在体内的组织分布差异,为其药理作用的研究及临床应用提供理论参考与借鉴.
The content levels of borneol,borneol-2-O-glucuronide(B2G),menthol,menthol-1-O-glucuronide(M1G),camphor,and glycyrrhizic acid in various rat tissue were determined after administration of Yanlishuang Oral Dripping Pills,and their distribution characteristics in different tissue were investigated.Normal SD rats were given Yanlishuang Oral Dripping Pills by gavage.Plasma and nine types of tissue(heart,liver,spleen,lung,kidney,intestine,brain,stomach,and pharynx)were collected at different time points after administration.Quantitative analysis methods using gas chromatography-mass spectrometry(GC-MS)and ultra-high performance liquid chromatography-tandem mass spectrometry(UPLC-MS/MS)were established to determine the content of the six components in plasma and tissue samples,and to compare the distribution differences among tissue.The results showed that all six prototype components and metabolites were absorbed into the blood and widely distributed in the body,reaching peak levels in plasma and tissue within 30 min and being gradually eliminated at 90 min.The prototype components borneol,menthol,and camphor were mainly distributed in the stomach and intestine;glycyrrhizic acid was mainly distributed in the stomach,intestine,and pharynx,with only small amounts in other tissue.The metabolites B2G and M1G were mainly distributed in the intestine,liver,and kidney.Among them,B2G and glycyrrhizic acid were more abundant in the pharynx.This study revealed the differences in tissue distribution of the prototype components and metabolites of Yanlishuang Oral Dripping Pills in vivo,providing theoretical reference for the study of its pharmacological effects and clinical application.
作者
曹玲
朱春先
袁红飞
迟明艳
黄勇
王爱民
郑林
李鸿迪
CAO Ling;ZHU Chun-xian;YUAN Hong-fei;CHI Ming-yan;HUANG Yong;WANG Ai-min;ZHENG Lin;LI Hong-di(State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine,Guizhou Medical University,Guiyang 550004,China;School of Pharmaceutical Sciences,Guizhou Medical University,Guiyang 550004,China;Guizhou Provincial Engineering Research Center for the Development and Application of Ethnic Medicine and Traditional Chinese Medicine,Guizhou Medical University,Guiyang 55O004,China;Huangguoshu-lishuang Pharmaceutical Co.,Ltd.,Guiyang 550004,China)
出处
《中国中药杂志》
北大核心
2025年第24期7004-7012,共9页
China Journal of Chinese Materia Medica
基金
贵州省科技重大专项项目(黔科合重大专项字[2024]015)
贵州省科技计划项目(黔科合支撑[2023]一般234,黔科合平台人才-GCC[2023]036)
贵州省科技创新团队项目(黔科合平台人才-CXTD[2023]019)
贵阳市科技计划项目(筑科合同[2024]2-35号)。
